Tenax Therapeutics regains compliance with Nasdaq minimum bid price rule

TENAX THERAPEUTICS, INC.

Received Nasdaq written confirmation on Jan 18, 2024, after 10 consecutive trading days (Jan 3-17) closing at $1.00 or greater.
Originally notified of bid price deficiency on March 29, 2023; later granted extension through March 25, 2024.
Compliance achieved ahead of extension deadline; delisting risk removed.
Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)) matter now closed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.